EMA Schedules High-Stakes Oral Explanation Meeting For Aducanumab Filing

 
• By Neena Brizmohun

The sponsors of aducanumab and three other drugs are set to explain why their EU marketing authorization applications merit approval during oral explanation meetings at the European Medicines Agency.

Wooden blocks with the word Review. Customer review concept. Reviewing, auditing, reviewer. Service rating. Feedback.
Aducanumab is at the latter stages of the EMA's regulatory review cycle • Source: Alamy

More from Europe

More from Geography